eFFECTOR Therapeutics’ Steve Worland to Speak March 24 at Ohio Wesleyan University
DELAWARE, Ohio – Steve Worland, Ph.D., co-founded San Diego-based eFFECTOR Therapeutics, Inc., in 2012 in an effort to develop a new type of treatment for cancer and other serious diseases – one that prevents the body from carrying out the harmful instructions of disease-triggering proteins.
Worland, eFFECTOR’s president and CEO, will discuss “The Importance of Alternative Perspectives in Business Ethics” when he presents Ohio Wesleyan University’s 2016 Heisler Business Ethics Lecture at 7:30 p.m. ET March 24. He will speak in Benes Room B of OWU’s Hamilton-Williams Campus Center, 40 Rowland Ave., Delaware.
Earlier that day, Worland will discuss “Entrepreneurship in the Biological Sciences” when he speaks to Ohio Wesleyan students as part of the university’s ongoing Science Lecture Series. This daytime presentation will be held at noon ET in Room 163 of Schimmel/Conrades Science Center, 90 S. Henry St., Delaware. Both presentations are free and open to the public.
In addition to his leadership of eFFECTOR Therapeutics, Worland also is a member of the board of directors for San Diego-based TRACON Pharmaceuticals, Inc., which is working to create therapeutics to treat cancer and vision-related diseases.
Prior to co-founding eFFECTOR Therapeutics, Worland served as president and CEO of Anadys Pharmaceuticals, Inc., which was developing treatments for Hepatitis C and cancer. The company was acquired by Roche in 2011. Worland began his healthcare industry career at Agouron Pharmaceuticals, Inc., and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer.
Worland earned his bachelor of science degree in biological chemistry from the University of Michigan and his doctoral degree in chemistry from the University of California, Berkeley. He later served as a National Institutes of Health postdoctoral fellow in molecular biology at Harvard University. Learn more about Worland and eFFECTOR Therapeutics at http://effector.com.
Ohio Wesleyan’s annual Heisler Business Ethics Lecture is funded by the Heisler Family Endowment for the Study of Ethics, which honors university graduates James Heisler, Class of 1938; Robert Heisler, Class of 1942; and Bruce Heisler, Class of 1949. The lecture is sponsored by the university’s Woltemade Center for Economics, Business and Entrepreneurship, which helps students to integrate business theory and practice, and provides lectures and other resources to benefit students, faculty, and the local community. The mission of The Woltemade Center is to enhance academic programming and provide real-world opportunities to create future business and world leaders. Learn more at www.owu.edu/woltemade.
Founded in 1842, Ohio Wesleyan University is one of the nation’s premier liberal arts universities. Located in Delaware, Ohio, the private university offers 87 undergraduate majors and competes in 23 NCAA Division III varsity sports. Ohio Wesleyan combines a challenging, internationally focused curriculum with off-campus learning and leadership opportunities to connect classroom theory with real-world experience. OWU’s 1,675 students represent 43 U.S. states and territories and 33 countries. Ohio Wesleyan is featured in the book “Colleges That Change Lives,” listed on the latest President’s Higher Education Community Service Honor Roll with Distinction, and included in the U.S. News & World Report and Princeton Review “best colleges” lists. Learn more at www.owu.edu.